Revolutionizing obesity treatment: The emerging role of GLP-1 receptor agonists and next-generation pharmacotherapies

Abstract

Purpose of review

This review examines the transformative impact of GLP-1 receptor agonists (GLP-1 RAs) in obesity management and evaluates emerging next-generation pharmacotherapies that are reshaping treatment paradigms. We synthesize current evidence on mechanisms, clinical efficacy, and integration strategies to provide clinicians and researchers with comprehensive guidance on modern obesity pharmacotherapy.

Recent findings

GLP-1 RAs, particularly semaglutide 2.4 mg, demonstrate unprecedented weight loss efficacy of 14.9% in clinical trials, surpassing traditional interventions. The dual GLP-1/GIP agonist tirzepatide achieves even superior outcomes with up to 22.5% weight reduction. Beyond weight loss, these agents provide substantial cardiovascular benefits, including 14% reduction in major adverse cardiovascular events and significant improvements in heart failure outcomes. Emerging triple agonists like retatrutide show promising 24% weight loss in early trials. Novel delivery systems, including oral formulations and extended-release preparations, are expanding treatment accessibility. Real-world studies confirm sustained efficacy but highlight challenges including cost barriers, supply shortages, and variable insurance coverage.

Summary

GLP-1 RAs represent a paradigm shift in obesity treatment, offering clinically meaningful weight loss with significant cardiometabolic benefits. Next-generation multi-agonist therapies promise enhanced efficacy through targeting multiple hormonal pathways. Successful clinical integration requires addressing implementation challenges including cost-effectiveness, patient selection, and long-term safety monitoring. These advances position pharmacotherapy as a cornerstone of comprehensive obesity management, complementing lifestyle and surgical interventions in a chronic disease treatment model.